Will U.S. consumers and retailers ever be ready for NFC? - Mobile Commerce Daily

By Staff reports

November 22, 2013

Please click here to sign up for Mobile Commerce Daily

Will U.S. consumers and retailers ever be ready for NFC?
Last year, experts thought that NFC was going to really take off this year, but recent moves from Google Wallet and Isis point to a significant question: Will NFC ever really take off?
Please click here to read the entire story on Mobile Commerce Daily

EBay envisions a world filled with mobile-enabled shoppable windows
EBay wants to scale up its Connected Glass program at the national and even international level, enabling consumers around the world to touch a glass window and shop products, with purchases completed from a mobile phone.?
Please click here to read the entire story on Mobile Commerce Daily

22pc of retail mobile sites miss the mark on SEO: report
While Amazon, Staples and Walmart are getting mobile redirects from search results right, others are not and risk being downgraded in Google search results, according to a new study from Pure Oxygen Labs.
Please click here to read the entire story on Mobile Commerce Daily

Gap expands omnichannel inventory program for added convenience
Gap and Banana Republic are expanding their ?Reserve in Store? pilot to help holiday shoppers save time by reserving items on-the-go and easily picking them up in-store.
Please click here to read the entire story on Mobile Commerce Daily

Please click here to sign up for Mobile Commerce Daily

View the original article here

Egg-Free Flu Vaccine Ready for Flu Season

By Todd Neale, Senior Staff Writer, MedPage Today

A new trivalent recombinant influenza vaccine has been added to the 2013-2014 flu recommendations to provide an immunization option for people with a history of allergic reactions to eggs.

Flublok is made using recombinant DNA technology and contains hemagglutinin produced in an insect cell line. Approved by the FDA in January, it is the only completely egg-free flu vaccine available, prompting the Advisory Committee on Immunization Practices (ACIP) to add it to the guidance for the upcoming season at one of its regular meetings at CDC headquarters in Atlanta.

According to the previous algorithm for determining how people with egg allergies should be vaccinated, those who had a history of only hives upon exposure to egg were recommended to get inactivated influenza vaccine followed by an observation period of at least 30 minutes after administration to watch for reactions.

And those who had a history of some other reaction aside from hives -- such as cardiovascular changes, respiratory distress, gastrointestinal symptoms, and reactions requiring epinephrine or emergency medical attention -- were recommended to see a physician with expertise in management of allergic conditions for further evaluation.

For the upcoming season -- following a unanimous vote by ACIP -- Flublok (abbreviated RIV3) will be listed as an alternative in both scenarios, assuming the individual falls within the approved age range of 18 to 49.

A reference to RIV3 also will be made in added language referring to people who do not have a history of egg allergy but who may be at risk based on previously performed allergy testing. In that case, "consultation with a physician with expertise in the management of allergic conditions should be obtained prior to vaccination" or, if age appropriate, RIV3 can be given.

At the last meeting of ACIP in February, the committee approved the addition of four recently approved flu vaccines to the guidance for the 2013-2014 season. On Thursday, Sanofi Pasteur's Fluzone Quadrivalent -- approved by the FDA earlier this month -- was added, as well. It is the only quadrivalent flu vaccine approved for use in children younger than 2.

All of the quadrivalent vaccines will protect against two A strains -- H1N1 and H3N2 -- and two B strains -- one from the Yamagata lineage and one from the Victoria lineage.

One of the ACIP members, Tamera Coyne-Beasley, MD, MPH, reported that her institution, the University of North Carolina at Chapel Hill, receives clinical trial funding from Merck. The other committee members reported that they had no conflicts of interest.

Todd Neale

Senior Staff Writer

Todd Neale, MedPage Today Staff Writer, got his start in journalism at Audubon Magazine and made a stop in directory publishing before landing at MedPage Today. He received a B.S. in biology from the University of Massachusetts Amherst and an M.A. in journalism from the Science, Health, and Environmental Reporting program at New York University.

Receive a digest of the day's essential medical news delivered to your inbox Sign Up Advertising Notice

This Site and third parties who place advertisements on this Site may collect and use information about your visits to this Site and other websites in order to provide advertisements about goods and services of interest to you. If you would like to obtain more information about these advertising practices and to make choices about online behavioral advertising, please

View the original article here